ArticleCureus2025
Transient Acquired von Willebrand Disease With a Type 2B Phenotype: Recognizing the Diagnostic Challenges.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acquired von Willebrand disease (vWD) may arise secondary to autoimmune conditions, hematologic malignancies, or valvular heart dysfunction. It should be included in the differential diagnosis of any acquired bleeding disorder. Most cases resemble Type 1 or Type 2A inherited vWD, typically presenting with variable decreases in von Willebrand antigen and activity. However, clinicians should exercise caution when interpreting von Willebrand panels to rule out acquired vWD, as acute phase reactants - associated with inflammation and malignancy - can artificially elevate and normalize circulating von Willebrand factor (vWF) and factor VIII levels. We present a rare case of acquired vWD with a Type 2B phenotype on platelet aggregation studies, temporally associated with diffuse large B-cell lymphoma (DLBCL). vWF and multimer assays were non-contributory, likely due to elevated acute phase reactants at the time of diagnosis, evidenced by increased factor VIII activity and falsely elevated von Willebrand antigen and activity levels. The patient's bleeding symptoms resolved following lymphoma treatment and remission. Platelet aggregation normalized, factor VIII levels returned to baseline, and von Willebrand activity stabilized. To the best of our knowledge, this case is the first to describe an association between acquired vWD with a Type 2B phenotype and DLBCL, expanding the range of hematologic malignancies linked to this rare presentation. We emphasize diagnostic challenges, particularly the role of acute-phase reactants in obscuring von Willebrand panel interpretations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.